Skip to main content

Published

Intravenous lanadelumab for the treatment of moderately ill COVID-19 patients.
Engel JJ. British Journal of Clinical Pharmacology 2026;92(6):1685-1695.
[Kallikrein-kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID-19-associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID-19, the authors conducted a phase 2, open-label, randomized-controlled, proof-of-concept, interventional trial.]
Freely available online

More details
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Hospital Ward
Intensive Care
Staff Groups
Medic
Pharmacist